This superselective intra-arterial cerebral infusion technique is already in use for the treatment of patients with recurrent malignant glioma in a phase I study and would present an alternative way to suppress CHKα independent from pharmacological compounds [53, 54]. This evidence concerns the gene CHKA and malignant glioma.